Skip to main content Accessibility help
×
Home

Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy

  • Ali Rabiei (a1), Hassan Yousefnia (a2), Samaneh Zolghadri (a2) and Mojtaba Shamsaei (a1)

Abstract

Aim

Bone-seeking radiopharmaceuticals are potential therapeutic tools for bone marrow ablation in patients with multiple myeloma. In this procedure, estimation of radiation absorbed dose received by the target and non-target organs is one of the most important parameters that should be undertaken. This research revolves around the absorbed dose to human organs after 90Y-BPAMD injection.

Materials and methods

90Y-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (90Y-BPAMD) complex was successfully prepared under optimised conditions. The human absorbed dose of the complex was estimated based on the biodistribution data on rats using the radiation-absorbed dose-assessment resource method. The target to non-target absorbed dose ratios for the complex was compared with the ratios for 166Ho-DOTMP, as the main radiopharmaceutical for bone marrow ablation.

Results

As expected, the highest amounts of absorbed dose were observed in the bone surface and the bone marrow with 2·52 and 2·29 mGy/MBq, respectively. The red marrow to the most organ absorbed dose ratios for 90Y-BPAMD are much higher than the ratios for 166Ho-DOTMP.

Findings

90Y-BPAMD has interesting characteristics compared with 166Ho-DOTMP and can be considered as a high potential agent for bone marrow ablative therapy of the patient with multiple myeloma.

Copyright

Corresponding author

Author for correspondence: Samaneh Zolghadri, E-mail: szolghadri@aeoi.org.ir

Footnotes

Hide All

Cite this article: Rabiei A, Yousefnia H, Zolghadri S, Shamsaei M. (2019) Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy. Journal of Radiotherapy in Practice18: 70–74. doi: 10.1017/S146039691800047X

Footnotes

References

Hide All
1. Alexanian, R, Dimopoulos, M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484489.
2. Nishiyama, Y, Tateishi, U, Shizukuishi, K et al. Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience. Ann Nucl Med 2013; 27: 7883.
3. Cascini, G L, Cuccurullo, V, Tamburrini, O et al. Nuclear medicine in multiple myeloma more than diagnosis. Nucl Med Rev Cent East Eur 2010; 13: 3238.
4. Cavo, M, Gobbi, M, Tura, S. Peptichemio in multiple myeloma. (Preliminary results). Haematologica 1981; 66: 208215.
6. Bayouth, J E, Macey, D J, Kasi, L P et al. Pharmacokinetics, dosimetry and toxicity of Holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995; 36: 730737.
7. Breitz, H B, Wendt, R E, Stabin, M S et al. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med 2006; 47: 534542.
8. Wiesmann, A, Einsele, H, Kanz, L, Dohmen, B M. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma. Bone Marrow Transplant 2005; 36: 8990.
9. Rabie, A, Enayati, R, Yousefnia, H et al. Preparation, quality control and biodistribution assessment of 153Sm-BPAMD as a novel agent for bone pain palliation therapy. Ann Nucl Med 2015; 29: 870876.
10. Fellnera, M, Biesalski, B, Bausbacher, N et al. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012; 39: 993999.
11. Fellner, M, Baum, R P, Kubícek, V et al. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010; 37: 834.
12. Yousefnia, H, Zolghadri, S, Sadeghi, H R et al. Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP. J Radioanal Nucl Chem 2016; 307: 12431251.
13. Macfarlane, D J, Durrant, S, Bartlett, M L et al. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002; 23: 10991106.
14. Vanhemert, F J, Sloof, G W, Schimmel, K J M et al. Radiopharmaceutical management of 90Y/111In labeled antibodies: shielding and quantification during preparation and administration. Ann Nucl Med 2006; 20: 575581.
15. Horovitz, C T. Biochemistry of Scandium and Yttrium, Part 2: Biochemistry and Applications. New York: Springer, 2000.
16. Ogawa, K, Kawashima, H, Shiba, K et al. Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol 2009; 36: 129135.
17. Környei, J, Antalffy, M, Baranyai, L. Opportunities in bone and joint therapy in the mirror of radiopharmaceuticals. www.cigota.rs/sites/default/files/abstract11.pdf. Accessed on 31st August 2018.
18. Rabiei, A, Shamsaei, M, Yousefnia, H et al. Development and biological evaluation of 90Y-BPAMD as a novel bone seeking therapeutic agent. Radiochimica Acta 2016; 104: 727734.
19. Pandey, U, Dhami, P S, Jagesia, P et al. Extraction paper chromatography technique for the radionuclidic purity evaluation of 90Y for clinical use. Anal Chem 2008; 80: 801807.
20. Yousefnia, H, Zolghadri, S, Jalilian, A R, Naseri, Z. Preliminary absorbed dose evaluation of two novel 153Sm bone-seeking agents for radiotherapy of bone metastases: comparison with 153Sm-EDTMP. J Radiother Pract 2015; 14: 252259.
21. Sparks, R B, Aydogan, B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities, 1996: 705716.
22. Stabin, M G, Siegel, J A. Physical models and dose factors for use in internal dose assessment. Health Phys 2003; 85: 294310.
23. Stabin, M G, Sparks, R B, Crowe, E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46: 10231027.
24. Brenner, D J. Effective dose: a flawed concept that could and should be replaced. Br J Radiol 2008; 81: 521523.
25. ICRP Publication 103. The 2007 recommendations of the international commission on radiological protection. Ann ICRP 2007; 37: 24.
26. Bélanger, M J, Krause, S M, Ryan, C et al. Biodistribution and radiation dosimetry of [18F]F-PEB in nonhuman primates. Nucl Med Commun 2008; 29: 915919.
27. Kesner, A L, Hsueh, W A, Czernin, J et al. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol 2008; 10: 341348.
28. Williams, LE. Radiopharmaceuticals: Introduction to Drug Evaluation and Dose Estimation. ISBN 9781439810675, Florida, USA: CRC Press, 2010.

Keywords

Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy

  • Ali Rabiei (a1), Hassan Yousefnia (a2), Samaneh Zolghadri (a2) and Mojtaba Shamsaei (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed